Canadian company's COVID-19 vaccine candidate begins clinical trial in Australia

  • 📰 CTVNews
  • ⏱ Reading Time:
  • 52 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 99%

Indonesia Berita Berita

Indonesia Berita Terbaru,Indonesia Berita utama

Canadian company Symvivo Corporation says it has begun clinical trials for its oral COVID-19 vaccine in Brisbane, Australia.

The company says bacTRL-Spike has two key advantages over other vaccines: it can be taken orally as a capsule instead of by injection, and it is stored at room temperature, bypassing cold-chain supply logistics.

"The rapidly advancing pandemic mandates innovative scientific approaches and we believe a safe, protective oral vaccine could transform the landscape of traditional vaccination approaches, eliminating the need for syringes, needles, and trained vaccinators," Sievers said in the release.$2.8 million from Canada’s National Research CouncilAccording to the press release, the Phase I trial is being conducted in partnership with Nucleus Network in Brisbane, Australia.

"Your mucosal immune response is really the first line of defense against viruses and other infectious diseases, and we have demonstrated the ability in our preclinical models to produce a mucosal response in addition to traditional systemic immune responses that other vaccines can induce," Graves said.

"When you could envision shipping this product [to] everybody's home around the world so that people can take it without medical oversight, we can actually get a viable vaccine solution globally," Graves said.

 

Terima kasih atas komentar Anda. Komentar Anda akan dipublikasikan setelah ditinjau.

It says in the article it is an oral DNA vaccine. Have any DNA vaccines ever been brought to market?

Why in australia CanadianPM

Why not in Canada? I have terminal prostate cancer currently with zero symptoms. I could be a candidate.

Trudeau and his gang should try it first

Berita ini telah kami rangkum agar Anda dapat membacanya dengan cepat. Jika Anda tertarik dengan beritanya, Anda dapat membaca teks lengkapnya di sini. Baca lebih lajut:

 /  🏆 1. in İD

Indonesia Berita Terbaru, Indonesia Berita utama